Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
10:56am, Friday, 13'th Sep 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questiona
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
09:52am, Wednesday, 11'th Sep 2024
Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
10:57am, Wednesday, 28'th Aug 2024
The consensus price target hints at a 307.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
7 Biotech Stocks to Buy for Their Game-Changing Potential
06:00am, Thursday, 08'th Aug 2024
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
09:25am, Thursday, 01'st Aug 2024
Precision BioSciences (DTIL) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of a loss of $0.77 per share. This compares to loss of $3 per share a year ago.
Precision BioSciences to Report Second Quarter Results on August 1, 2024
04:15pm, Monday, 29'th Jul 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies,
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
07:01am, Monday, 08'th Jul 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies,
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies,
Precision BioSciences to Participate in Upcoming June Investor Conferences
07:00am, Thursday, 30'th May 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
10:56am, Wednesday, 29'th May 2024
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
01:38am, Monday, 20'th May 2024
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 17'th May 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies f
